To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Flexibility and Efficiency with Tecan Integration Group
Read time: Less than a minute
Siena Biotech has chosen four Tecan Freedom EVO® workstations for different roles in drug development. Built by the Tecan Integration Group (TIG), each system has been invaluable in increasing throughput in testing compounds as potential therapeutic drugs.
Marta Gherardi from the Compound Management Group explained: “We chose our Freedom EVO systems to improve throughput, customized to exactly meet our needs by TIG. We visited TIG and looked at all the possibilities for customization, choosing the ones that best suited us. The instruments were then built in Switzerland before being integrated with our other systems on-site.”
Federico Cappelli from the Biomolecular Screening Group added: “We are still at the early stages of setting up some of the different applications on our Freedom EVO system, and we are currently working on automating our Madin-Darby canine kidney (MDCK) cell line permeability assays in collaboration with the Met Profiling Group. The flexibility of the system will allow us to reproduce the results already obtained by a dedicated operator, increase the throughput and minimize inter-operator variability.”
Marta Gherardi from the Compound Management Group explained: “We chose our Freedom EVO systems to improve throughput, customized to exactly meet our needs by TIG. We visited TIG and looked at all the possibilities for customization, choosing the ones that best suited us. The instruments were then built in Switzerland before being integrated with our other systems on-site.”
Federico Cappelli from the Biomolecular Screening Group added: “We are still at the early stages of setting up some of the different applications on our Freedom EVO system, and we are currently working on automating our Madin-Darby canine kidney (MDCK) cell line permeability assays in collaboration with the Met Profiling Group. The flexibility of the system will allow us to reproduce the results already obtained by a dedicated operator, increase the throughput and minimize inter-operator variability.”
